MacroGenics (MGNX)
(Delayed Data from NSDQ)
$3.39 USD
+0.09 (2.73%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $3.38 -0.01 (-0.29%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Brokerage Reports
0 items in cart
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 141 - 160 ( 363 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
Biotechnology- ASCO Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Company: MacroGenics, Inc.
Industry: Medical - Products
ASCO Abstract Should Eliminate Concerns on Approvability
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
SOPHIA ASCO Abstract Shows PFS Benefit, Trend to OS
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: MacroGenics, Inc.
Industry: Medical - Products
UPGRADING to OP; ASCO Here We Go (for Marge Data)!
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
1Q19 Corporate Update; SOPHIA Presentation at the ASCO Remains the Near-Term Sentiment Driver
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: MacroGenics, Inc.
Industry: Medical - Products
Thoughts Post AACR; Optionalities for Margetuximab and Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
The Year That Was Laying the Foundation for the Year That Already Is
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Biotechnology - AACR Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: MacroGenics, Inc.
Industry: Medical - Products
The Unfortunate Peer Stumble Highlights the Importance of the Measured Approach Implemented for Flotetuzumab
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: MacroGenics, Inc.
Industry: Medical - Products
DOWNGRADING to NEUTRAL: Approval Near Certain, and Baked in at These Levels
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
SOPHIA Delivers a Superior Trastuzumab; no Mean Feat; Target up to $39
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Expectations at the Nadir Heading Into the SOPHIA Phase 3 Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.